Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Full-scale manufacturing validation of BCMA CAR + CD38 CCR T cells for multiple myeloma
NL-OMON58462Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of BCMA CAR + CD38 CCR T cells in multiple myeloma (MM), sponsored by Amsterdam University Medical Center. Primary endpoint: Manufacturing success of CAR/CCR T cells. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
BCMA CAR + CD38 CCR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON58462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58462.